Stock 9926 AKESO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Akeso, Inc.

Equities

9926

KYG0146B1032

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
48.45 HKD +2.11% Intraday chart for Akeso, Inc. +3.64% +4.42%
Apr. 24 Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator MT
Apr. 24 National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer
Akeso to Raise Over HK$1 Billion Via Share Sale
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC
Akeso Books First-Ever Profit in 2023; Shares Fall 5%
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3%
Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI
Akeso, Inc. Announces Innovative Clinical Development Roadmap
Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer
Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023
Akeso Publishes Results from Three Investigator-Initiated Trials
Akeso Launches Construction of Shanghai Global R&D Center to Accelerate its Innovation Globalization Strategy
Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival for First-Line Treatment of Recurrent/Metastatic Cervical Cancer
Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)
Akeso, Inc. Announces A Phase III Trial of Cadonilimab in Combination with Chemotherapy as First Line Treatment for GASTRIC or Gastesophageal Junction Adenocarcinoma (GC/GEJC) Reaches Primary Endpoint of Overall Survival
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 9926 Stock
  4. News Akeso, Inc.
  5. Other languages